{
  "docId": "019de076-5923-773b-8485-b914b8e85d5b",
  "docSlug": "aa767e092bc23262b7b522a6b0c001e5",
  "documentTitle": "MindMed | Results Presentation Deck | 20 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 20,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a bar chart to visualize effect sizes, with a supporting text box explaining the methodology and context.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5923-773b-8485-b914b8e85d5b/15",
  "deckHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b",
  "deckJsonHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b.json",
  "deckAnchorHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Reported Mean Effect Size by Existing Therapeutic Drug Class",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28b9246a-87d4-4c17-bbaf-421b9647a3e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.38,
        "x": 0.58,
        "y": 0.2
      },
      "kind": "list",
      "text": "Effect size (ES) presents the adjusted to the mean difference in treatment response between placebo and active treatment. ES useful to compare overall treatment effects across trials. Results from published review of effect sizes for double-blind, placebo-controlled trials of GAD treatments primarily using HAM-A as the main outcome measure. SSRIs and benzodiazepines, the major therapeutic classes of drugs approved for GAD, have mean effect sizes that range between 0.36 to 0.38",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26ea28c5-72f8-4d4d-958a-415af64adc4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Examination of baseline group assignment... 2. Source: RB Hidalgo... 3. ES is calculated by dividing...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b18a8f7-2f9a-4735-9147-374d43bce71b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "* = P <0.05",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fef82a62-9d04-4b97-a026-8c88d83e0fb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MM-120 | Illustrative Analysis of Pharmacologic Treatments for GAD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e3fb389-b210-4b99-a2a5-a2da2b661704",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 15,
      "beatId": "7eed3be3-4cb2-423a-8635-c5a0198e60ee",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 15-19 discuss the potential impact, trial design milestones, and financial results.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}